drugset / Trial / NCT06144606
Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Phase 2
Recruiting
60 enrolled
H. Lee Moffitt Cancer Center and Research Institute
Kite, A Gilead Company · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase 2 Study is to determine the efficacy and safety rate of B-Cell Acute Lymphoblastic Leukemia (B-ALL) participants in remission with minimal residual disease (MRD) after KTE-X19 CAR T-cell therapy
Timeline
- Start
- 2023-12-26
- Primary completion
- 2031-07-29
- Completion
- 2031-07-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Brexucabtagene Autoleucel | Cell therapy | 1e+06 cells/kg | — |
| Subject | Brexucabtagene Autoleucel | Cell therapy | 1e+08 cells | — |